In a world-first international trial, adding intismeran, a type of personalized therapeutic cancer vaccine made from each patient’s own tumor, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%.
Related Posts
Children who eat more ultraprocessed foods show stronger brain responses to appetizing foods
Children who eat more ultraprocessed foods (UPFs) show stronger responses in the brain’s reward network when viewing images of appetizing foods—and these brain responses are […]
Digestive tract cancer “dissolved” after immunotherapy, after that steered clear of
Individuals with a certain type of digestive tract cancer remained without reappearance for nearly 3 years after getting a short program of immunotherapy before surgery, […]
Scientists are starting to unravel the most important genetic risk factor for Alzheimer’s
A gene variant called APOE4 dramatically increases the risk of late-onset Alzheimer’s disease, the most common form of dementia. Now, emerging research is revealing APOE4’s […]